Lipocine (LPCN) Short Interest Ratio & Short Volume → With revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radar (From Stocks News) (Ad) Free LPCN Stock Alerts $5.35 +0.07 (+1.33%) (As of 05/14/2024 ET) Add Compare Share Share Short InterestStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Lipocine Short Interest DataCurrent Short Volume181,000 sharesPrevious Short Volume278,400 sharesChange Vs. Previous Month-34.99%Dollar Volume Sold Short$836,220.00Short Interest Ratio / Days to Cover2.8Last Record DateApril 30, 2024Outstanding Shares5,350,000 sharesFloat Size5,190,000 sharesShort Percent of Float3.49%Today's Trading Volume20,635 sharesAverage Trading Volume56,113 sharesToday's Volume Vs. Average37% Short Selling Lipocine ? Sign up to receive the latest short interest report for Lipocine and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatLPCN Short Interest Over TimeLPCN Days to Cover Over TimeLPCN Percentage of Float Shorted Over Time Ad Stocks NewsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarRevolutionizing communication is what this NASDAQ-traded next-gen solution provider is doing. See how this company is well-positioned to capitalize in 2024 Lipocine Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/2024181,000 shares $836,220.00 -35.0%3.5%2.8 $4.62 4/15/2024278,400 shares $1.49 million +155.7%5.4%4.5 $5.36 3/31/2024108,900 shares $566,280.00 -11.9%2.1%3.6 $5.20 3/15/2024123,600 shares $568,560.00 +11.6%2.4%4.1 $4.60 2/29/2024110,800 shares $422,148.00 -15.4%2.1%4.3 $3.81 2/15/2024131,000 shares $525,310.00 -8.8%2.5%5.2 $4.01 Get the Latest News and Ratings for LPCN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter. 1/31/2024143,600 shares $560,040.00 +31.5%2.8%5.2 $3.90 1/15/2024109,200 shares $378,924.00 -2.1%2.1%4 $3.47 12/31/2023111,500 shares $311,085.00 -7.2%2.2%6.4 $2.79 12/15/2023120,100 shares $325,471.00 -8.7%2.3%7.2 $2.71 11/30/2023131,600 shares $317,156.00 -14.6%2.6%8.2 $2.41 11/15/2023154,100 shares $420,693.00 +18.5%3.0%7.8 $2.73 10/31/2023130,000 shares $331,500.00 -5.6%2.5%6.2 $2.55 10/15/2023137,700 shares $388,314.00 -8.0%2.7%0.8 $2.82 9/30/2023149,700 shares $446,106.00 +14.6%2.9%0.9 $2.98 9/15/2023130,600 shares $475,384.00 +52.0%2.5%0.8 $3.64 8/31/202385,900 shares $339,305.00 -12.3%1.7%0.5 $3.95 8/15/202397,900 shares $489,500.00 -66.9%1.9%0.6 $5.00 7/31/2023296,100 shares $1.47 million +361.2%5.9%1.7 $4.97 7/15/202364,200 shares $277,344.00 -22.0%1.3%2.5 $4.32 6/30/202382,300 shares $414,792.00 +2.2%1.6%3.1 $5.04 6/15/202380,500 shares $412,965.00 -25.8%1.6%3.1 $5.13 5/31/2023108,500 shares $502,355.00 +35.5%2.1%3.9 $4.63 5/15/202380,100 shares $343,629.00 +32.0%1.6%3.1 $4.29 4/30/20231,030,000 shares $267,800.00 -7.2%1.2%5.3 $0.26 4/15/20231,110,000 shares $316,683.00 -4.3%1.3%6.4 $0.29 3/31/20231,160,000 shares $368,996.00 -7.9%1.4%6.7 $0.32 3/15/20231,260,000 shares $389,214.00 -2.3%1.5%7.3 $0.31 2/28/20231,290,000 shares $582,177.00 -6.5%1.5%10.7 $0.45 2/15/20231,380,000 shares $707,940.00 -0.7%1.6%11.7 $0.51 1/31/20231,390,000 shares $736,700.00 -2.8%1.6%10.3 $0.53 1/15/20231,430,000 shares $795,366.00 -3.4%1.7%10 $0.56 12/30/20221,480,000 shares $588,744.00 -1.3%1.7%11.1 $0.40 12/15/20221,500,000 shares $662,100.00 -7.4%1.7%9.2 $0.44 11/30/20221,620,000 shares $729,162.00 +3.9%1.9%8.7 $0.45 11/15/20221,560,000 shares $645,996.00 -3.1%1.8%7.8 $0.41 10/31/20221,610,000 shares $658,490.00 -2.4%1.9%6.6 $0.41 10/15/20221,650,000 shares $742,500.00 No Change1.9%6.5 $0.45 9/30/20221,650,000 shares $742,500.00 -13.6%1.9%6.5 $0.45 9/15/20221,910,000 shares $1.11 million +4.4%2.2%8 $0.58The Crypto 9-5 Escape Plan (Ad)A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide LPCN Short Interest - Frequently Asked Questions What is Lipocine's current short interest? Short interest is the volume of Lipocine shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 181,000 shares of LPCN short. 3.49% of Lipocine's shares are currently sold short. Learn More on Lipocine's current short interest. What is a good short interest ratio for Lipocine? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. LPCN shares currently have a short interest ratio of 3.0. Learn More on Lipocine's short interest ratio. What is a good short interest percentage for Lipocine? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 3.49% of Lipocine's floating shares are currently sold short. Is Lipocine's short interest increasing or decreasing? Lipocine saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 181,000 shares, a drop of 35.0% from the previous total of 278,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Lipocine's float size? Lipocine currently has issued a total of 5,350,000 shares. Some of Lipocine's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Lipocine currently has a public float of 5,190,000 shares. How does Lipocine's short interest compare to its competitors? 3.49% of Lipocine's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Lipocine: DURECT Co. (3.24%), Theratechnologies Inc. (0.10%), Enlivex Therapeutics Ltd. (1.42%), JanOne Inc. (2.00%), Biora Therapeutics, Inc. (4.52%), Acasti Pharma Inc. (0.02%), Unity Biotechnology, Inc. (2.16%), Viracta Therapeutics, Inc. (2.54%), ImmunoPrecise Antibodies Ltd. (1.45%), Daré Bioscience, Inc. (0.29%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Lipocine stock? Short selling LPCN is an investing strategy that aims to generate trading profit from Lipocine as its price is falling. LPCN shares are trading up $0.07 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Lipocine? A short squeeze for Lipocine occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of LPCN, which in turn drives the price of the stock up even further. How often is Lipocine's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LPCN, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: DURECT Short Interest Theratechnologies Short Interest Enlivex Therapeutics Short Interest JanOne Short Interest Biora Therapeutics Short Interest Acasti Pharma Short Interest Unity Biotechnology Short Interest Viracta Therapeutics Short Interest ImmunoPrecise Antibodies Short Interest Daré Bioscience Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:LPCN) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe A.I. story nobody is telling you (Read ASAP)TradeSmithBuy this small stock before coming AI Tidal WaveChaikin AnalyticsElon’s New Device is About to Shock the WorldInvestorPlaceCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap Sniper